Render Target: STATIC
Render Timestamp: 2024-11-21T13:24:55.795Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:57:21.447
Product last modified at: 2024-11-07T13:00:13.398Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

RAI17/ZMIZ1 (E2X3X) Rabbit mAb #89500

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H M Mk
    SENSITIVITY Endogenous
    MW (kDa) 120, 130
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    RAI17/ZMIZ1 (E2X3X) Rabbit mAb recognizes endogenous levels of total RAI17/ZMIZ1 protein.

    Species Reactivity:

    Human, Mouse, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro902 of human RAI17/ZMIZ1 protein.

    Background

    ZMIZ1, also known as ZIMP10 or RAI17, is a member of the Protein Inhibitor of Activated STAT (PIAS)-like family of transcriptional coregulators (1). ZMIZ1 was initially discovered as a novel coregulator of the androgen receptor (AR) and was shown to augment AR activity by enhancing sumoylation of the receptor (2). Subsequent studies have shown that ZMIZ1 can also act as a transcriptional coactivator of p53 (3) and SMAD3 (4). During thymopoiesis, ZMIZ1 was shown to promote pre-T-cell proliferation through cooperative induction of a subset of NOTCH target genes (5). In T-cell acute lymphoblastic leukemia (T-ALL) cells, ZMIZ1 was shown to engage directly with NOTCH1 through an N-terminal tetratricopeptide repeat (TPR) domain, facilitating its recruitment to a long-range acting enhancer element to promote MYC transcription and activity. Moreover, inhibition of ZMIZ1 impaired the initiation and maintenance of NOTCH-induced T-ALL (6). Although NOTCH1 appears to rely on ZMIZ1 to selectively amplify an oncogenic subset of target genes, research studies suggest ZMIZ1 is not involved in NOTCH-mediated intestinal homeostasis or myeloid suppression, suggesting that therapeutic strategies targeting ZMIZ1 may provide an opportunity to indirectly target NOTCH-driven cancers, with reduced adverse effects (7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.